# Phase 3 Trial of Cannabidiol (CBD; GWP42003-P) for Infantile Spasms: Open-label Extension Phase (GWPCARE7)

> **NCT02954887** · PHASE3 · COMPLETED · sponsor: **Jazz Pharmaceuticals** · enrollment: 9 (actual)

## Conditions studied

- Infantile Spasms

## Interventions

- **DRUG:** GWP42003-P

## Key facts

- **NCT ID:** NCT02954887
- **Lead sponsor:** Jazz Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-05-12
- **Primary completion:** 2019-06-13
- **Final completion:** 2019-06-13
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2022-09-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02954887

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02954887, "Phase 3 Trial of Cannabidiol (CBD; GWP42003-P) for Infantile Spasms: Open-label Extension Phase (GWPCARE7)". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT02954887. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*